- Molnupiravir results are striking for very early treatment, but this doesn't compare with vaccination; the time window for effect is short and the trial was mostly with unvaccinated people.
- Merck has a Phase 3 trial testing if molnupiravir can prevent infection of a person exposed to someone infected with COVID-19.
- The commercial opportunities for COVID-19 remain primarily in the vaccine area; molnupiravir will have a role, but will it move the needle for Merck in the longer term?
For further details see:
Merck Stock Up On Molnupiravir, But Don't Get Too Excited